Associate Professor Will Herrington is a Medical Research Council-Kidney Research UK Professor David Kerr clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. His research aims focus on better understanding the key determinants of kidney diseases, cardiovascular diseases and their interrelatedness using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors. Since 2014, he has worked on the Mexico City Prospective Study, a 150,000 person blood-based cohort with nearly 20 years of follow-up for cause-specific mortality. He is also a trialist and is Chief Investigator of the EMPA-KIDNEY trial, which is testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease, has chaired the UK Renal Trials Network since 2020 and is a section editor for NDT.